HUMAN GENOME SCIENCES RECEIVES MILESTONE PAYMENTS FROM GLAXOSMITHKLINE FOR GSK716155 PROGRESS

Human Genome Sciences, Inc. announced today that it has received $7 million in payments from its collaborator, GlaxoSmithKline (GSK), related to the achievement of manufacturing and preclinical development milestones for GSK716155 (formerly known as Albugon), a drug currently in late-stage preclinical development for potential use in the treatment of diabetes. The Company received and recognized $2 million as revenue in the second quarter of 2005, and will recognize the remaining $5 million as revenue in the third quarter of 2005.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=260784)